{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:27:04Z","timestamp":1790875624148,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"AriBio Co. Ltd.","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alzheimer\u2019s disease (AD) pathology is associated with complex interactions among multiple factors, involving an intertwined network of various signaling pathways. The polypharmacological approach is an emerging therapeutic strategy that has been proposed to overcome the multifactorial nature of AD by targeting multiple pathophysiological factors including amyloid-\u03b2 (A\u03b2) and phosphorylated tau. We evaluated a blood-brain barrier penetrating phosphodiesterase 5 (PDE5) inhibitor, mirodenafil (5-ethyl-2-7-n-propyl-3,5-dihydrro-4H-pyrrolo[3,2-d]pyrimidin-4-one), for its therapeutic effects on AD with polypharmacological properties.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To evaluate the potential of mirodenafil as a disease-modifying AD agent, mirodenafil was administered to test its effects on the cognitive behaviors of the APP-C105 AD mouse model using the Morris water maze and passive avoidance tests. To investigate the mechanisms of action that underlie the beneficial disease-modifying effects of mirodenafil, human neuroblastoma SH-SY5Y cells and mouse hippocampal HT-22 cells were used to show mirodenafil-induced alterations associated with the cyclic guanosine monophosphate (cGMP)\/cGMP-dependent protein kinase (PKG)\/cAMP-responsive element-binding protein (CREB) pathway, apoptotic cell death, tau phosphorylation, amyloidogenesis, the autophagy-lysosome pathway, glucocorticoid receptor (GR) transcriptional activity, and the Wnt\/\u03b2-catenin signaling.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, mirodenafil is demonstrated to improve cognitive behavior in the APP-C105 mouse model. Mirodenafil not only reduced the A\u03b2 and phosphorylated tau burdens in vivo, but also ameliorated AD pathology induced by A\u03b2 through the modulation of the cGMP\/PKG\/CREB signaling pathway, glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) activity, GR transcriptional activity, and the Wnt\/\u03b2-catenin signaling in neuronal cells. Interestingly, homodimerization and nuclear localization of GR were inhibited by mirodenafil, but not by other PDE5 inhibitors. In addition, only mirodenafil reduced the expression levels of the Wnt antagonist Dickkopf-1 (Dkk-1), thus activating the Wnt\/\u03b2-catenin signaling.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings strongly suggest that the PDE5 inhibitor mirodenafil shows promise as a potential polypharmacological drug candidate for AD treatment, acting on multiple key signaling pathways involved in amyloid deposition, phosphorylated tau burden, the cGMP\/PKG\/CREB pathway, GSK-3\u03b2 kinase activity, GR signaling, and the Wnt\/\u03b2-catenin signaling. Mirodenafil administration to the APP-C105 AD mouse model also improved cognitive behavior, demonstrating the potential of mirodenafil as a polypharmacological AD therapeutic agent.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01034-3","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:02:38Z","timestamp":1657256558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions"],"prefix":"10.1186","volume":"14","author":[{"given":"Byung Woo","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseol","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Jun","family":"Choung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"5","key":"1034_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Collaborators GBDN","year":"2019","unstructured":"Collaborators GBDN. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1034_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/alz.12450","volume":"18","author":"JL Cummings","year":"2022","unstructured":"Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer\u2019s disease: A retrospective exploration. Alzheimers Dement. 2022;18(3):469\u201377.","journal-title":"Alzheimers Dement."},{"issue":"11","key":"1034_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682\u201390.","journal-title":"Nat Chem Biol"},{"issue":"4","key":"1034_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016;164(4):603\u201315.","journal-title":"Cell."},{"issue":"3","key":"1034_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s12035-015-9143-0","volume":"53","author":"ZX Wang","year":"2016","unstructured":"Wang ZX, Tan L, Liu J, Yu JT. The Essential Role of Soluble Abeta Oligomers in Alzheimer's Disease. Mol Neurobiol. 2016;53(3):1905\u201324.","journal-title":"Mol Neurobiol"},{"issue":"29","key":"1034_CR6","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1523\/JNEUROSCI.5291-04.2005","volume":"25","author":"D Puzzo","year":"2005","unstructured":"Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide\/cGMP\/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci. 2005;25(29):6887\u201397.","journal-title":"J Neurosci"},{"issue":"7","key":"1034_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419\u201334.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1034_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/nan.12203","volume":"41","author":"A Ugarte","year":"2015","unstructured":"Ugarte A, Gil-Bea F, Garcia-Barroso C, Cedazo-Minguez A, Ramirez MJ, Franco R, et al. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathol Appl Neurobiol. 2015;41(4):471\u201382.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"25","key":"1034_CR9","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","volume":"29","author":"D Puzzo","year":"2009","unstructured":"Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci. 2009;29(25):8075\u201386.","journal-title":"J Neurosci"},{"key":"1034_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","volume":"64","author":"C Garcia-Barroso","year":"2013","unstructured":"Garcia-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, et al. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology. 2013;64:114\u201323.","journal-title":"Neuropharmacology."},{"issue":"8","key":"1034_CR11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","volume":"164","author":"M Cuadrado-Tejedor","year":"2011","unstructured":"Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Perez-Roldan JM, Garcia-Barroso C, et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. Br J Pharmacol. 2011;164(8):2029\u201341.","journal-title":"Br J Pharmacol"},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","volume":"250","author":"J Zhang","year":"2013","unstructured":"Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice. Behav Brain Res. 2013;250:230\u20137.","journal-title":"Behav Brain Res"},{"issue":"4","key":"1034_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3233\/JAD-161006","volume":"60","author":"M Sheng","year":"2017","unstructured":"Sheng M, Lu H, Liu P, Li Y, Ravi H, Peng SL, et al. Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease. J Alzheimers Dis. 2017;60(4):1351\u201364.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"1034_CR14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","volume":"1","author":"J Fang","year":"2021","unstructured":"Fang J, Zhang P, Zhou Y, Chiang C-W, Tan J, Hou Y, et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease. Nat Aging. 2021;1(12):1175\u201388.","journal-title":"Nat Aging"},{"issue":"11","key":"1034_CR15","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1111\/j.1743-6109.2008.00945.x","volume":"5","author":"JS Paick","year":"2008","unstructured":"Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med. 2008;5(11):2672\u201380.","journal-title":"J Sex Med"},{"issue":"8","key":"1034_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1745-7254.2007.00611.x","volume":"28","author":"HH Yoo","year":"2007","unstructured":"Yoo HH, Kim NS, Im GJ, Kim DH. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta Pharmacol Sin. 2007;28(8):1247\u201353.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"1034_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10571-005-4937-7","volume":"25","author":"HJ Lim","year":"2005","unstructured":"Lim HJ, Cho JS, Oh JH, Shim SB, Hwang DY, Jee SW, et al. NSE-controlled carboxyl-terminus of APP gene over-expressing in transgenic mice induces altered expressions in behavior, Abeta-42, and GSK3beta binding proteins. Cell Mol Neurobiol. 2005;25(5):833\u201350.","journal-title":"Cell Mol Neurobiol"},{"issue":"10","key":"1034_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ncb1001-905","volume":"3","author":"L Puglielli","year":"2001","unstructured":"Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3(10):905\u201312.","journal-title":"Nat Cell Biol"},{"issue":"10","key":"1034_CR19","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1096\/fj.00-0859fje","volume":"15","author":"SH Choi","year":"2001","unstructured":"Choi SH, Park CH, Koo JW, Seo JH, Kim HS, Jeong SJ, et al. Memory impairment and cholinergic dysfunction by centrally administered Abeta and carboxyl-terminal fragment of Alzheimer's APP in mice. FASEB J. 2001;15(10):1816\u20138.","journal-title":"FASEB J"},{"issue":"7","key":"1034_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1046\/j.0953-816x.2001.01735.x","volume":"14","author":"MM Kraus","year":"2001","unstructured":"Kraus MM, Prast H. The nitric oxide system modulates the in vivo release of acetylcholine in the nucleus accumbens induced by stimulation of the hippocampal fornix\/fimbria-projection. Eur J Neurosci. 2001;14(7):1105\u201312.","journal-title":"Eur J Neurosci"},{"key":"1034_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-62703-640-5_2","volume":"1078","author":"J Kovalevich","year":"2013","unstructured":"Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9\u201321.","journal-title":"Methods Mol Biol"},{"issue":"9-10","key":"1034_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.lfs.2008.12.008","volume":"84","author":"J Liu","year":"2009","unstructured":"Liu J, Li L, Suo WZ. HT22 hippocampal neuronal cell line possesses functional cholinergic properties. Life Sci. 2009;84(9-10):267\u201371.","journal-title":"Life Sci"},{"issue":"10","key":"1034_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024839","volume":"6","author":"P Kay","year":"2011","unstructured":"Kay P, Schlossmacher G, Matthews L, Sommer P, Singh D, White A, et al. Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. PLoS One. 2011;6(10):e24839.","journal-title":"PLoS One"},{"issue":"13","key":"1034_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jlcr.1116","volume":"49","author":"H-I Shin","year":"2006","unstructured":"Shin H-I, Lee J, Kim D-K. Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin-4-one\u00b72 HCl (14C-SK3530\u00b72 HCl). J Labelled Compounds Radiopharm. 2006;49(13):1141\u20139.","journal-title":"J Labelled Compounds Radiopharm"},{"key":"1034_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.03.071","volume":"553","author":"SJ Lee","year":"2021","unstructured":"Lee SJ, Shizu R, Negishi M. Glucocorticoid receptor dimerization in the cytoplasm might be essential for nuclear localization. Biochem Biophys Res Commun. 2021;553:154\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"1034_CR26","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","volume":"19","author":"YF Lu","year":"1999","unstructured":"Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci. 1999;19(23):10250\u201361.","journal-title":"J Neurosci"},{"issue":"4","key":"1034_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0896-6273(00)81010-7","volume":"20","author":"X Tao","year":"1998","unstructured":"Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20(4):709\u201326.","journal-title":"Neuron."},{"issue":"9","key":"1034_CR28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1096\/fj.03-1378fje","volume":"18","author":"K Sambamurti","year":"2004","unstructured":"Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 2004;18(9):1034\u20136.","journal-title":"FASEB J"},{"issue":"11","key":"1034_CR29","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1074\/jbc.M109.087866","volume":"285","author":"S Robertson","year":"2010","unstructured":"Robertson S, Allie-Reid F, Vanden Berghe W, Visser K, Binder A, Africander D, et al. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. J Biol Chem. 2010;285(11):8061\u201375.","journal-title":"J Biol Chem"},{"issue":"3","key":"1034_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001813","volume":"12","author":"DM Presman","year":"2014","unstructured":"Presman DM, Ogara MF, Stortz M, Alvarez LD, Pooley JR, Schiltz RL, et al. Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLoS Biol. 2014;12(3):e1001813.","journal-title":"PLoS Biol"},{"issue":"1","key":"1034_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41398-018-0231-6","volume":"8","author":"C Elliott","year":"2018","unstructured":"Elliott C, Rojo AI, Ribe E, Broadstock M, Xia W, Morin P, et al. A role for APP in Wnt signalling links synapse loss with beta-amyloid production. Transl Psychiatry. 2018;8(1):179.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"1034_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/toxsci\/kfr304","volume":"125","author":"M Moors","year":"2012","unstructured":"Moors M, Bose R, Johansson-Haque K, Edoff K, Okret S, Ceccatelli S. Dickkopf 1 mediates glucocorticoid-induced changes in human neural progenitor cell proliferation and differentiation. Toxicol Sci. 2012;125(2):488\u201395.","journal-title":"Toxicol Sci"},{"issue":"6835","key":"1034_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/35077108","volume":"411","author":"B Mao","year":"2001","unstructured":"Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411(6835):321\u20135.","journal-title":"Nature."},{"key":"1034_CR34","doi-asserted-by":"crossref","unstructured":"Nortley R, Korte N, Izquierdo P, Hirunpattarasilp C, Mishra A, Jaunmuktane Z, et al. Amyloid beta oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. Science. 2019;365(6450):eaav9518.","DOI":"10.1126\/science.aav9518"},{"issue":"1","key":"1034_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2007.01.039","volume":"416","author":"M Kamouchi","year":"2007","unstructured":"Kamouchi M, Kitazono T, Ago T, Wakisaka M, Kuroda J, Nakamura K, et al. Hydrogen peroxide-induced Ca2+ responses in CNS pericytes. Neurosci Lett. 2007;416(1):12\u20136.","journal-title":"Neurosci Lett"},{"issue":"11","key":"1034_CR36","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1021\/cn3000907","volume":"3","author":"A Garcia-Osta","year":"2012","unstructured":"Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, Oyarzabal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci. 2012;3(11):832\u201344.","journal-title":"ACS Chem Neurosci"},{"issue":"25","key":"1034_CR37","doi-asserted-by":"publisher","first-page":"14220","DOI":"10.1073\/pnas.2003277117","volume":"117","author":"JJS VerPlank","year":"2020","unstructured":"VerPlank JJS, Tyrkalska SD, Fleming A, Rubinsztein DC, Goldberg AL. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc Natl Acad Sci U S A. 2020;117(25):14220\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1034_CR38","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1111\/bph.14205","volume":"175","author":"KE Andersson","year":"2018","unstructured":"Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554\u201365.","journal-title":"Br J Pharmacol"},{"issue":"5448","key":"1034_CR39","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1126\/science.286.5448.2358","volume":"286","author":"A Riccio","year":"1999","unstructured":"Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science. 1999;286(5448):2358\u201361.","journal-title":"Science."},{"issue":"49","key":"1034_CR40","doi-asserted-by":"publisher","first-page":"40398","DOI":"10.1074\/jbc.C500140200","volume":"280","author":"J Lee","year":"2005","unstructured":"Lee J, Kim CH, Simon DK, Aminova LR, Andreyev AY, Kushnareva YE, et al. Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J Biol Chem. 2005;280(49):40398\u2013401.","journal-title":"J Biol Chem"},{"key":"1034_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fnins.2018.00739","volume":"12","author":"G Canet","year":"2018","unstructured":"Canet G, Chevallier N, Zussy C, Desrumaux C, Givalois L. Central Role of Glucocorticoid Receptors in Alzheimer's Disease and Depression. Front Neurosci. 2018;12:739.","journal-title":"Front Neurosci"},{"key":"1034_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1750-1326-3-9","volume":"3","author":"NC Inestrosa","year":"2008","unstructured":"Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener. 2008;3:9.","journal-title":"Mol Neurodegener"},{"issue":"26","key":"1034_CR43","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.1381-04.2004","volume":"24","author":"A Caricasole","year":"2004","unstructured":"Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;24(26):6021\u20137.","journal-title":"J Neurosci"},{"issue":"19","key":"1034_CR44","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.cub.2016.07.024","volume":"26","author":"A Marzo","year":"2016","unstructured":"Marzo A, Galli S, Lopes D, McLeod F, Podpolny M, Segovia-Roldan M, et al. Reversal of Synapse Degeneration by Restoring Wnt Signaling in the Adult Hippocampus. Curr Biol. 2016;26(19):2551\u201361.","journal-title":"Curr Biol"},{"issue":"6774","key":"1034_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/35004606","volume":"404","author":"J Schlossmann","year":"2000","unstructured":"Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, et al. Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta. Nature. 2000;404(6774):197\u2013201.","journal-title":"Nature."},{"issue":"2","key":"1034_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish PV, Steadman D, Bayle ED, Whiting P. New approaches for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2019;29(2):125\u201333.","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"1034_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737175.2019.1621751","volume":"19","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Watling M, Imbimbo BP. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother. 2019;19(7):599\u2013602.","journal-title":"Expert Rev Neurother"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01034-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T06:08:11Z","timestamp":1657260491000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01034-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were carried out in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We have read the journal\u2019s policy and the authors of this manuscript have the following competing interests: B.W.K, F.K., J.R., and J.J.C. are employees at AriBio, Co. Ltd. SY. K. is a paid consultant to AriBio, Co. Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}